Aktuellt
SENASTE
Q3 confirms that Vitrolife is going through a period with softer organic growth, even below our expectations, at 3% in Q3. The main challenge is Genetic Services and the US growth in particular. Despite weaker growth, Vitrolife delivers gross margins and EBITDA margins above expectations, and the growth is about to normalize gradually over the next twelve months. We expect a negative initial reaction.
LÄS MER
